Brigatinib
CAS 1197953-54-0Small Molecule
Overview
Brigatinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL3545311).
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Brigatinib expires 10 Nov 2035 and exclusivity 22 May 2027. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine
- Canonical SMILES
- CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
- InChIKey
- AILRADAXUVEEIR-UHFFFAOYSA-N
Verified Supplier Partner
Do you supply Brigatinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.